1-15 of 15
Rosemary Gale
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Clinical Trials & Observations
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D. Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D’Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H. Russell, Richard Dillon
Journal: Blood
Blood (2024) 144 (7): 714–728.
https://doi.org/10.1182/blood.2024024310
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Clinical Trials & Observations
Richard Dillon, Robert Hills, Sylvie Freeman, Nicola Potter, Jelena Jovanovic, Adam Ivey, Anju Shankar Kanda, Manohursingh Runglall, Nicola Foot, Mikel Valganon, Asim Khwaja, Jamie Cavenagh, Matthew Smith, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Steven Knapper, Harpreet Kaur, David Taussig, Priyanka Mehta, Kavita Raj, Igor Novitzky-Basso, Emmanouil Nikolousis, Robert Danby, Pramila Krishnamurthy, Kate Hill, Damian Finnegan, Samah Alimam, Erin Hurst, Peter Johnson, Anjum Khan, Rahuman Salim, Charles Craddock, Ruth Spearing, Amanda Gilkes, Rosemary Gale, Alan Burnett, Nigel H. Russell, David Grimwade
Journal: Blood
Blood (2020) 135 (9): 680–688.
https://doi.org/10.1182/blood.2019002959
Published: 2020
Includes: Supplemental data
Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell
Journal: Blood
Blood (2018) 132 (Supplement 1): 664.
https://doi.org/10.1182/blood-2018-99-116482
Published: 2018
Journal Articles

Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Alan K. Burnett, MD, Rosemary Gale, PhD, David C. Linch, Amanda Gilkes, Nigel H. Russell
Journal: Blood
Blood (2018) 132 (Supplement 1): 1392.
https://doi.org/10.1182/blood-2018-99-116542
Published: 2018
Journal Articles

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

Clinical Trials & Observations Brief Report
Kate Stringaris, David Marin, A. John Barrett, Robert Hills, Catherine Sobieski, Kai Cao, Jerome G. Saltarrelli, May Daher, Hila Shaim, Nathaniel Smith, David Linch, Rosemary Gale, Christopher Allen, Takuya Sekine, Rohtesh Mehta, Richard Champlin, Elizabeth J. Shpall, Hagop Kantarjian, Guillermo Garcia-Manero, Katayoun Rezvani
Journal: Blood
Blood (2016) 128 (24): 2819–2823.
https://doi.org/10.1182/blood-2016-05-713099
Published: 2016
Includes: Supplemental data
Journal Articles

Disease evolution and outcomes in familial AML with germline CEBPA mutations

Kiran Tawana, Jun Wang, Aline Renneville, Csaba Bödör, Robert Hills, Chey Loveday, Aleksandar Savic, Frederik W. Van Delft, Jennifer Treleaven, Panayiotis Georgiades, Elizabeth Uglow, Norio Asou, Naokuni Uike, Maruša Debeljak, Janez Jazbec, Philip Ancliff, Rosemary Gale, Xavier Thomas, Valerie Mialou, Konstanze Döhner, Lars Bullinger, Beatrice Mueller, Thomas Pabst, Matthias Stelljes, Brigitte Schlegelberger, Eva Wozniak, Sameena Iqbal, Jessica Okosun, Shamzah Araf, Anne-Katrine Frank, Felicia B. Lauridsen, Bo Porse, Claus Nerlov, Carolyn Owen, Inderjeet Dokal, John Gribben, Matthew Smith, Claude Preudhomme, Claude Chelala, Jamie Cavenagh, Jude Fitzgibbon
Journal: Blood
Blood (2015) 126 (10): 1214–1223.
https://doi.org/10.1182/blood-2015-05-647172
Published: 2015
Includes: Supplemental data
Journal Articles

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Kate Stringaris, MD, MRCP, FRCPath, A. John Barrett, MD, Robert Hills, MA, MSc, DPhil, David C Linch, MD, FMedSci, Rosemary Gale, PhD, Christopher Allen, Paula Garland, MBBS, MRCP, Ruhena Sargent, Hugues de Lavallade, Abdullah Alsuliman, Ahmad Khoder, Dr, Ian H Gabriel, Dr, Takuya Sekine, Alan Burnett, Katayoun Rezvani, Jane F. Apperley
Journal: Blood
Blood (2010) 116 (21): 1697.
https://doi.org/10.1182/blood.V116.21.1697.1697
Published: 2010
Journal Articles

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Claire L Green, Catherine M Evans, Robert Hills, MA, MSc, DPhil, Lu Zhao, Alan Burnett, David C Linch, MD, Rosemary Gale, PhD
Journal: Blood
Blood (2010) 116 (21): 100.
https://doi.org/10.1182/blood.V116.21.100.100
Published: 2010
Journal Articles

Estimating the Replication Rate of Hematopoietic Stem Cells (HSC) In Vivo.

Janis L. Abkowitz, MD, Sandra N Catlin, PhD, Rosemary Gale, PhD, Lambert Busque, MD, Peter Guttorp, PhD
Journal: Blood
Blood (2009) 114 (22): 2522.
https://doi.org/10.1182/blood.V114.22.2522.2522
Published: 2009
Journal Articles

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

Carol Guy, Amanda Gilkes, Rosemary Gale, PhD, David C. Linch, FRCP, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP
Journal: Blood
Blood (2008) 112 (11): 2978.
https://doi.org/10.1182/blood.V112.11.2978.2978
Published: 2008
Journal Articles

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Marc R Mansour, MBChB, MRCP, Rosemary Gale, PhD, Asim Khwaja, Martin Pule, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP, David Linch
Journal: Blood
Blood (2008) 112 (11): 3364.
https://doi.org/10.1182/blood.V112.11.3364.3364
Published: 2008
Journal Articles

FLT3 ITD and TKD Mutations Differ in Their Functional Consequence in Both Cell Line Models and Primary Hematopoietic Cells

Adam J Mead, Asim Khwaja, Rosemary Gale, PhD, David C. Linch, FRCP
Journal: Blood
Blood (2008) 112 (11): 3791.
https://doi.org/10.1182/blood.V112.11.3791.3791
Published: 2008
Journal Articles

The Relationship Between Wild Type and Mutant-Positive Platelets in Essential Thrombocythemia Patients with a JAK2 V617F Mutation

Jonathan R Lambert, MRCP, Rosemary Gale, PhD, David C. Linch, FRCP
Journal: Blood
Blood (2008) 112 (11): 3728.
https://doi.org/10.1182/blood.V112.11.3728.3728
Published: 2008
Journal Articles

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD, Robert Hills, MA, MSc, DPhil, Claire Green, Yashma Patel, Amanda Gilkes, Michelle Lazenby, Keith Wheatley, DPhil, David C. Linch, FRCP, Alan Burnett
Journal: Blood
Blood (2008) 112 (11): 554.
https://doi.org/10.1182/blood.V112.11.554.554
Published: 2008
Journal Articles

Favourable Prognosis Associated with FLT3 Tyrosine Kinase Domain Mutations in AML in Contrast to the Adverse Outcome Associated with Internal Tandem Duplications.

Adam Mead, David Linch, Robert Hills, Keith Wheatley, Alan Burnett, Rosemary Gale
Journal: Blood
Blood (2005) 106 (11): 334.
https://doi.org/10.1182/blood.V106.11.334.334
Published: 2005